Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
golidocitinib + pegaspargase + gemcitabine + oxaliplatin + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Dizal Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This experimental combination regimen is being investigated for the first-line treatment of advanced or non-nasal extranodal NK/T-cell lymphoma (ENKTL). It integrates **golidocitinib**, a selective Janus kinase 1 (JAK1) inhibitor that targets the STAT3 signaling pathway frequently dysregulated in NK/T-cell malignancies, with the established **P-GemOx** cytotoxic backbone (comprising pegaspargase, gemcitabine, and oxaliplatin) and a **PD-1 inhibitor**. The regimen is designed to achieve synergistic anti-lymphoma activity by simultaneously inhibiting oncogenic signaling, depleting essential asparagine, inducing DNA damage, and reversing immune exhaustion. The combination is currently being evaluated in a Phase 2 multicenter trial led by investigator Wei Xu to determine if the addition of JAK1 inhibition and checkpoint blockade to standard chemotherapy improves complete response rates in treatment-naive patients.
- Other names
- Golidocitinib + P-GemOx + PD-1 inhibitor
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)JAK1 (Janus kinase 1)DNA
Beyond the preview
Go deeper on golidocitinib + pegaspargase + gemcitabine + oxaliplatin + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on golidocitinib + pegaspargase + gemcitabine + oxaliplatin + PD-1 inhibitor.